Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3201 Target Snapshot

Aryl hydrocarbon receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
755Compounds
246Assays
1Approved Drugs
488.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Aryl hydrocarbon receptor shows approved-linked disease relevance led by psoriasis. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P35869. Start with psoriasis, then reuse UniProt P35869 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with psoriasis, then reuse UniProt P35869 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
psoriasis

Aryl hydrocarbon receptor shows approved-linked disease relevance led by psoriasis. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with psoriasis because it currently carries approved-linked support. Linked drugs include TAPINAROF. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Aryl hydrocarbon receptor as ChEMBL target CHEMBL3201, mapped to UniProt P35869. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Aryl hydrocarbon receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3201
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P35869
Aryl hydrocarbon receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Aryl hydrocarbon receptor is the right protein anchor across sources, using UniProt P35869 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why psoriasis is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameAryl hydrocarbon receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP35869
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAryl hydrocarbon receptor
UniProt AccessionP35869
Component TypeProtein
Sequence Length848 aa

Aryl hydrocarbon receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Aryl hydrocarbon receptor, mapped to UniProt P35869. Sequence length is 848 aa.

Mapped IDP35869
Review nameAryl hydrocarbon receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Aryl hydrocarbon receptor shows approved-linked disease relevance led by psoriasis. 1 more disease program remain visible in the same review block.

Approved-linked Approved
psoriasis
1 linked drug · 1 direct · 1 efficacy
Linked drugTAPINAROF
Late clinical Phase III
atopic eczema
1 linked drug · 1 direct · 1 efficacy
Linked drugTAPINAROF
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with psoriasis because it currently carries approved-linked support. Linked drugs include TAPINAROF. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasepsoriasis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
3
Phase III
2
Phase II
3
Phase I
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC5031.0
KI38.0
EC50413.0
KD6.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5289699 11.0 EC50 0.01 Preclinical
CHEMBL5203882 10.52 EC50 0.03 Preclinical
CHEMBL472031 10.15 Kd 0.07 Preclinical
CHEMBL5285977 10.01 EC50 0.0971 Preclinical
CHEMBL4580482 9.89 Kd 0.13 Preclinical
CHEMBL5270440 9.86 EC50 0.137 Preclinical
CHEMBL5597486 9.81 EC50 0.154 Preclinical
CHEMBL5266782 9.79 EC50 0.161 Preclinical
CHEMBL5265853 9.72 EC50 0.189 Preclinical
CHEMBL509307 9.72 Kd 0.19 Preclinical
Distribution

pChEMBL Value Distribution

65
5.0
66
5.5
40
6.0
47
6.5
33
7.0
21
7.5
8
8.0
12
8.5
11
9.0
19
9.5
pChEMBL
Approved Drugs

Approved Drugs

TAPINAROF
CHEMBL259571
Approved 2022
Properties Compare Identifier
Assay Landscape

Assay Landscape

246
Total Assays
240
Tested Compounds
4
Assay Types
Binding — 179 assays, 240 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 130 97 7.0
single protein format 37 130 6.8
assay format 7 5 7.4
subcellular format 4 6 9.7
tissue-based format 1 2 5.8
ADME — 58 assays, 108 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 39 108 5.7
single protein format 13 0 —
assay format 6 0 —
Functional — 7 assays, 16 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 5 9 5.5
cell-based format 2 7 6.3
Toxicity — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine